Rest assured that they looked at multiple doses early on before settling on 350mg. They may have made that work public, I don’t know, but it’s a common process within drug development to look at safety at higher doses as well as efficacy. It’s likely that as more information was gathered it became clear (like seeing what happened to patients in CD12 after two weeks and LL leaving their system) that a higher dose for specific patients or reasons was either necessary or at least worth looking into. Recknor seems to have played a big part in trying to gather smart data from our trials and I suspect we’ll continue to see dosing tweaked to some extent over time.

If nobody was allowed to learn anything or adjust their efforts once trials were underway we wouldn’t have Viagra, which was supposed to be for blood pressure until trial participants started reporting their hard-ons. They make their best guesses, run some studies, and then move on. In many cases they learn new stuff along the way and adjust. That’s where we’re at with LL.